Melanoma in solid organ transplant recipients

Area of Science:

• Oncology
• Transplant Surgery
• Dermatology

Background:

• Melanoma (MM) risk and outcomes in transplant recipients are not fully understood.
• Understanding pretransplant, donor-transmitted, and de novo MM is crucial for patient management.

Purpose of the Study:

• To estimate the risk and clinical course of melanoma in transplant recipients.
• To analyze risk factors for metastasis and evaluate current management strategies.

Main Methods:

• Review of clinical studies on melanoma in the transplant population.
• Analysis of risk factors for metastasis and clinical course.
• Evaluation of current and proposed management strategies, including immunosuppression revision.

Main Results:

• In situ and thin melanoma (<1 mm) in transplant patients show similar recurrence and survival rates to the general population.
• A 2-year waiting period post-melanoma treatment is suggested for transplantation if melanoma is <1 mm and non-metastatic.
• Advanced melanoma may exhibit a more aggressive course in transplant recipients.

Conclusions:

• Early-stage melanoma in transplant patients has favorable outcomes, but advanced disease warrants caution.
• Sentinel lymph node biopsy may offer prognostic value.
• Management requires collaboration between transplant and oncology teams, with potential immunosuppression adjustments.
• Further research with standardized criteria is needed to fully assess melanoma risk in immunosuppressed transplant patients.